MetaCap

Aquestive Therapeutics (AQST) vs DiaMedica Therapeutics (DMAC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DiaMedica Therapeutics (DMAC) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 8.1% versus a loss of 39.5%. Over five years, DMAC leads with a +118.8% price change compared with -45.7% for AQST. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $434.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%DMAC+8.13%
+46%-4%-53%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%DMAC+115.97%
+158%+28%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus DMAC key metrics
MetricAQSTDMAC
Share price$3.46$8.25
Market cap$434.88M$445.15M
1-day change-6.61%+2.87%
YTD return-46.44%+3.64%
1-year return-39.51%+8.13%
5-year return-45.68%+118.83%
EPS (TTM)$-0.65$-0.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M—
Revenue growth (YoY)-22.61%—
Net income (latest FY)$-83.78M$-32.77M
Gross margin58.35%—
Operating margin-159.50%—
Net margin-188.09%—
52-week high$6.74$11.00
52-week low$2.93$5.25
Distance from 52-week high-48.63%-25.00%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+169.65%+96.97%
Average volume2.41M210.46K
Shares outstanding125.69M53.96M
Employees14735
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMAC has outperformed AQST by 47.6 percentage points over the past year.

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About DiaMedica Therapeutics

DMAC stock →

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

AQST vs DMAC FAQ

Which is bigger, Aquestive Therapeutics or DiaMedica Therapeutics?

DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $434.88M for Aquestive Therapeutics (AQST).

Which stock has performed better over the past year, AQST or DMAC?

DMAC returned +8.13% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and DiaMedica Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons